San Ramon, CA-September 30, 2009
Nextrials, Inc.
, has upgraded its electronic data capture and clinical trial management platform, Prism. In addition to its new user interface, Prism now offers expanded functionality and interoperability with electronic health records from multiple vendors.
Prism users will see differences to its start page, where researchers can now evaluate project data from multiple studies organized into modules that can be collapsed and expanded for review. The “at a glance” statistics roll-up bar is intended to provide users with fast facts, such as enrollment status and data quality metrics. And with Prism’s newly streamlined structure, pop-up windows have been reduced in favor of intuitive layers within the browser.
A significant change to Prism is its interoperability with data platforms more traditionally found within the healthcare environment for creating and managing electronic medical records. This gives life science companies many more options for implementing studies using patients and sites. Also, major incentives included in the American Recovery and Reinvestment Act (ARRA) will further promote the adoption of electronic medical records.
Nextrials expanded Prism’s report generation functionality earlier in the year to give users more powerful data mining capabilities. This ad hoc reporting feature has been further enhanced so that customers can now share reports with others, more easily monitor study progress and even drill down to analyze underlying data.
Prism 3.0 will continue to support mobile access to data via the Apple iPhone. Nextrials expects Prism 3.0 to be in general availability before the end of the year. However, attendees at the 2009 Society for Clinical Data Management Annual Conference, being held at the Westin Seattle (WA) Hotel October 4-6, can get a first look at Nextrials’ Prism 3.0 in booth #301 and #303.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.